---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-020233"
form_type: "8-K"
ticker: "LENZ"
cik: "0001815776"
company_name: "LENZ Therapeutics, Inc."
filed_at: "2022-05-16T23:59:59+00:00"
generated_at: "2026-06-25T15:23:50.692147+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Graphite Bio presents preclinical GPH102 data for beta-thalassemia; HDR rates up to 40%

## Summary
- Preclinical gene replacement data for GPH102 presented at ASGCT; HDR rates up to 40% in sickle cell HSPCs restoring HbA expression.
- GPH102 aims to replace mutated beta-globin gene to treat beta-thalassemia, targeting IND submission by mid-2024.
- Encore poster for GPH101 Phase 1/2 CEDAR trial for sickle cell disease also presented at ASGCT.
- Data accepted for encore presentation at EHA 2022 Hybrid Congress in June.

## SEC filing metadata
- accession: 0001564590-22-020233
- form_type: 8-K
- ticker: LENZ
- cik: 0001815776
- company_name: LENZ Therapeutics, Inc.
- filed_at: 2022-05-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815776/000156459022020233/0001564590-22-020233-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815776/000156459022020233/grph-8k_20220516.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-020233
- JSON: https://secwatch.observer/filing/0001564590-22-020233.json
- Plain text: https://secwatch.observer/filing/0001564590-22-020233.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.